drugset / Trial / NCT04505592
Tenecteplase in Patients With COVID-19
RandomizedSequentialTriple-blindTreatment
Summary
This is a placebo-controlled, double blind, randomized, Phase II dose escalation study intended to evaluate the potential safety and efficacy of tenecteplase for the treatment of COVID-19 associated respiratory failure. The hypothesis is that administration of the drug, in conjunction with heparin anticoagulation, will improve patients' clinical outcomes.
Timeline
- Start
- 2020-09-25
- Primary completion
- 2022-03-10
- Completion
- 2022-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 0.5 mg/kg | Intravenous |